Novel costimulatory bispecific antibody shows encouraging anti-tumor activity when combined with pd-1 inhibitor libtayo® (cemiplimab) in advanced metastatic castration-resistant prostate cancer (mcrpc)

First clinical data from ongoing phase 1/2 trial show dose-dependent anti-tumor activity for investigational regn5678 (psmaxcd28) when combined with standard dose libtayo, suggesting potential to overcome mcrpc resistance to pd-1 inhibition anti-cancer activity correlated with immune-related adverse events these data provide early evidence and proof of principle for regeneron's broader costimulatory bispecific platform, which includes three cd28 bispecifics in ongoing clinical trials and additional candidates in preclinical development tarrytown, n.y. , aug. 3, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced encouraging initial data from an ongoing phase 1/2 trial investigating regn5678, a novel psmaxcd28 costimulatory bispecific antibody, in combination with the company's pd-1 inhibitor libtayo® (cemiplimab) in advanced metastatic castration-resistant prostate cancer (mcrpc).
REGN Ratings Summary
REGN Quant Ranking